Benzimidazole derivatives
The present invention relates to a compound of the Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3A , R 3B , R 4 , R 5 , X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
1. A compound of Formula II(a),
wherein:
each R 1 is independently halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —CF 3 , —CN, or —NR 16 R 17 ;
R 2 is hydrogen or (C 1 -C 6 )alkyl;
R 3B is hydrogen, (C 1 -C 6 )alkyl, —(CH 2 ) t (C 6 -C 12 )aryl, or —(CH 2 ) t (C 3 -C 12 )carbocyclyl;
R 4 is hydrogen or (C 1 -C 6 )alkyl;
R 10 is —(CH 2 ) t (C 6 -C 12 )aryl or —(CH 2 ) t (4 to 14 membered heterocyclyl), wherein each of said (C 6 -C 12 )aryl and (4 to 14 membered heterocyclyl) is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C 1 -C 6 )alkyl, —CN, halo, —CF 3 , —OCF 3 , —NR 16 R 17 , (C 1 -C 6 )alkoxy, —NO 2 , —(CH 2 ) t (C 6 -C 12 )aryl, —C(O)(C 1 -C 6 alkyl), —C(O)CF 3 , azido, (4 to 12 membered heterocyclyl), and —S((C 1 -C 6 )alkyl);
each R 16 and R 17 is independently selected from hydrogen and (C 1 -C 6 )alkyl;
n is 0, 1, 2, 3, or 4; and
each t is independently 0, 1, or 2; or
a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 , wherein:
each R 1 is independently F, Cl, Br, —CH 3 , —OCH 3 , —CF 3 , —CN, or —NR 16 R 17 ;
R 2 is hydrogen;
R 3B is hydrogen, —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , or —CH 2 (phenyl);
R 4 is hydrogen; and
R 10 is phenyl, pyridyl, or 2,3-dihydro-1,4-benzodioxinyl, wherein each of said phenyl, pyridyl, and 2,3-dihydro-1,4-benzodioxinyl is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C 1 -C 6 )alkyl, —CN, halo, —CF 3 , —OCF 3 , —NR 16 R 17 , (C 1 -C 6 )alkoxy, —NO 2 , —(CH 2 ) t (C 6 -C 12 )aryl, —C(O)(C 1 -C 6 alkyl), —C(O)CF 3 , azido, (4 to 12 membered heterocyclyl), and —S((C 1 -C 6 )alkyl); or
a pharmaceutically acceptable salt thereof.
3. A compound according to claim 2 , wherein:
each R 1 is independently F, Cl, —CH 3 , —OCH 3 , —CF 3 , —CN, or —N(CH 3 ) 2 ;
R 3B is —CH 3 ; and
R 10 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, or 2,3-dihydro-1,4-benzodioxin-6-yl, wherein each of said phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and 2,3-dihydro-1,4-benzodioxin-6-yl is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C 1 -C 6 )alkyl, —CN, halo, —CF 3 , —OCF 3 , —NR 16 R 17 , (C 1 -C 6 )alkoxy, —NO 2 , —(CH 2 ) t (C 6 -C 12 )aryl, —C(O)(C 1 -C 6 alkyl), —C(O)CF 3 , azido, (4 to 12 membered heterocyclyl), and —S((C 1 -C 6 )alkyl); or
a pharmaceutically acceptable salt thereof.
4. A compound according to claim 3 , wherein R 10 is phenyl, 3-pyridyl, or 2,3-dihydro-1,4-benzodioxin-6-yl, wherein each of said phenyl, 3-pyridyl, and 2,3-dihydro-1,4-benzodioxin-6-yl is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C 1 -C 6 )alkyl, —CN, halo, —CF 3 , —OCF 3 , —NR 16 R 17 , (C 1 -C 6 )alkoxy, —NO 2 , —(CH 2 ) t (C 6 -C 12 )aryl, —C(O)(C 1 -C 6 alkyl), —C(O)CF 3 , azido, (4 to 12 membered heterocyclyl), and —S((C 1 -C 6 )alkyl); or a pharmaceutically acceptable salt thereof.
5. A compound according to claim 4 , wherein R 10 is phenyl optionally substituted with from 1 to 5 substituents each of which is independently selected from (C 1 -C 6 )alkyl, —CN, halo, —CF 3 , —OCF 3 , —NR 16 R 17 , (C 1 -C 6 )alkoxy, —NO 2 , —(CH 2 ) t (C 6 -C 12 )aryl, —C(O)(C 1 -C 6 alkyl), —C(O)CF 3 , azido, (4 to 12 membered heterocyclyl), and —S((C 1 -C 6 )alkyl); or a pharmaceutically acceptable salt thereof.
6. A compound according to claim 5 , wherein R 10 is phenyl optionally substituted with from 1 to 5 substituents each of which is independently selected from —CH 3 , —CN, —F, —Cl, —Br, —CF 3 , —OCF 3 , —NR 16 R 17 , —OCH 3 , and —NO 2 ; or a pharmaceutically acceptable salt thereof.
7. A compound of Formula III(a),
wherein:
each R 1 is independently halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —CF 3 , —CN, or —NR 16 R 17 ;
R 2 is hydrogen or (C 1 -C 6 )alkyl;
R 3B is hydrogen, (C 1 -C 6 )alkyl, —(CH 2 ) t (C 6 -C 12 )aryl, or —(CH 2 ) t (C 3 -C 12 )carbocyclyl;
R 4 is hydrogen or (C 1 -C 6 )alkyl;
R 11 is —(CH 2 ) t (C 6 -C 12 )aryl or —(CH 2 ) t (4 to 14 membered heterocyclyl), wherein each of said (C 6 -C 12 )aryl and (4 to 14 membered heterocyclyl) is optionally substituted with from 1 to 5 substituents each of which is independently selected from (C 1 -C 6 )alkyl, —CN, halo, —CF 3 , —OCF 3 , —NR 16 R 17 , (C 1 -C 6 )alkoxy, —NO 2 , —(CH 2 ) t (C 6 -C 12 )aryl, —C(O)(C 1 -C 6 alkyl), —C(O)CF 3 , azido, (4 to 12 membered heterocyclyl), and —S((C 1 -C 6 )alkyl);
each R 16 and R 17 is independently selected from hydrogen and (C 1 -C 6 )alkyl;
n is 0, 1, 2, 3, or 4; and
each t is independently 0, 1, or 2; or
a pharmaceutically acceptable salt thereof.
8. A compound of Formula IV(a)
wherein:
each R 1 is independently halo, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, —CF 3 , —CN, or —NR 16 R 17 ;
R 2 is hydrogen or (C 1 -C 6 )alkyl;
R 3B is hydrogen, (C 1 -C 6 )alkyl, —(CH 2 ) t (C 6 -C 12 )aryl, or —(CH 2 ) t (C 3 -C 12 )carbocyclyl;
R 4 is hydrogen or (C 1 -C 6 )alkyl;
each R 12 is independently selected from —(CH 2 ) t (C 6 -C 12 )aryl, —(CH 2 ) t (4 to 14 membered heterocyclyl), (C 1 -C 6 )alkyl, —CN, halo, —CF 3 , —OCF 3 , —NR 16 R 17 , (C 1 -C 6 )alkoxy, —NO 2 , —(CH 2 ) t (C 6 -C 12 )aryl, —C(O)(C 1 -C 6 alkyl), —C(O)CF 3 , azido, (4 to 12 membered heterocyclyl), and —S((C 1 -C 6 )alkyl);
each R 16 and R 17 is independently selected from hydrogen and (C 1 -C 6 )alkyl;
n is 0, 1, 2, 3, or 4;
each t is independently 0, 1, or 2; and
z is 0, 1, 2, 3, 4, or 5; or
a pharmaceutically acceptable salt thereof.
9. A compound according to claim 8 , wherein:
R 2 is hydrogen;
R 3B is —CH 3 ;
R 4 is hydrogen; and
each R 12 is independently selected from —CN, —F, —Cl, —Br, —CF 3 , —OCF 3 , —NR 16 R 17 , —OCH 3 , and —NO 2 ; or
a pharmaceutically acceptable salt thereof.
10. A compound according to claim 9 , wherein:
each R 1 is independently halo, —CH 3 , —OCH 3 , —CF 3 , —CN, or —N(CH 3 ) 2 ;
R 12 is —CN, —F, —Cl, —Br, —CF 3 , —OCF 3 , —OCH 3 , or —NO 2 ; and
z is 1; or
a pharmaceutically acceptable salt thereof.
11. A compound according to claim 10 , wherein:
R 12 is —CN, —F, —Cl, —Br, or —CF 3 ; and
n is 0; or
a pharmaceutically acceptable salt thereof.
12. A compound according to claim 11 , wherein R 12 is —CN, or a pharmaceutically acceptable salt thereof.
13. A compound selected from:
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea;
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-chlorophenyl)urea;
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(6-fluoropyridin-3-yl)urea;
N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]chromane-6-carboxamide;
N-[(2R,4R)-2-(6-chloro-1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
1-{(2R,4R)-1-methyl-2-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]piperidin-4-yl}-3-[6-(trifluoromethyl)pyridin-3-yl]urea;
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-methoxyphenyl)urea;
N-[(2R,4R)-2-(6-methoxy-1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide;
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-isobutylpiperidin-4-yl]-3-(4-cyanophenyl)urea; and
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(6-fluoro-5-methylpyridin-3-yl)urea; or
a pharmaceutically acceptable salt thereof.
14. A compound which is
or a pharmaceutically acceptable salt thereof.
15. A compound which is
or a pharmaceutically acceptable salt thereof.
16. A compound which is
or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition, comprising an effective amount of at least one compound according to claim 1 , and a pharmaceutically acceptable carrier.